(0.25%) 5 144.50 points
(0.28%) 38 547 points
(0.36%) 17 909 points
(-0.82%) $83.16
(1.30%) $1.948
(-0.13%) $2 344.20
(1.22%) $27.59
(0.63%) $927.90
(-0.28%) $0.932
(-0.25%) $11.00
(-0.40%) $0.797
(0.85%) $92.66
0.00% HKD 18.00
Live Chart Being Loaded With Signals
SciClone Pharmaceuticals (Holdings) Limited, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products in the therapeutic areas of oncology and severe infection in Mainland China and internationally...
Stats | |
---|---|
Dagens volum | 2.82M |
Gjennomsnittsvolum | 4.21M |
Markedsverdi | 10.97B |
EPS | HKD0 ( 2023-08-17 ) |
Last Dividend | HKD0.390 ( 2023-06-02 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 9.68 |
ATR14 | HKD0.0170 (0.09%) |
Volum Korrelasjon
SciClone Pharmaceuticals, Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
SciClone Pharmaceuticals, Korrelasjon - Valuta/Råvare
SciClone Pharmaceuticals, Økonomi
Annual | 2023 |
Omsetning: | HKD3.16B |
Bruttogevinst: | HKD2.36B (74.67 %) |
EPS: | HKD1.720 |
FY | 2023 |
Omsetning: | HKD3.16B |
Bruttogevinst: | HKD2.36B (74.67 %) |
EPS: | HKD1.720 |
FY | 2022 |
Omsetning: | HKD2.75B |
Bruttogevinst: | HKD2.07B (75.30 %) |
EPS: | HKD1.270 |
FY | 2021 |
Omsetning: | HKD2.52B |
Bruttogevinst: | HKD1.93B (76.75 %) |
EPS: | HKD1.420 |
Financial Reports:
No articles found.
SciClone Pharmaceuticals, Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.390 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.350 | 2022-05-27 |
Last Dividend | HKD0.390 | 2023-06-02 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 2 | -- |
Total Paid Out | HKD0.740 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.31 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 6.58 | |
Div. Directional Score | 9.28 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
9909.HK | Ex Dividend Knight | 2023-11-24 | Semi-Annually | 0 | 0.00% | |
2161.HK | Ex Dividend Junior | 2023-08-15 | Annually | 0 | 0.00% | |
1161.HK | Ex Dividend Knight | 2023-06-12 | Annually | 0 | 0.00% | |
0239.HK | Ex Dividend Knight | 2023-09-29 | Semi-Annually | 0 | 0.00% | |
3866.HK | Ex Dividend Junior | 2023-06-02 | Annually | 0 | 0.00% | |
1731.HK | Ex Dividend Junior | 2023-06-23 | Sporadic | 0 | 0.00% | |
0771.HK | Ex Dividend Junior | 2023-05-31 | Sporadic | 0 | 0.00% | |
2327.HK | Ex Dividend Junior | 2023-08-03 | Sporadic | 0 | 0.00% | |
1290.HK | Ex Dividend Junior | 2023-06-14 | Sporadic | 0 | 0.00% | |
0363.HK | Ex Dividend Knight | 2023-06-01 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.356 | 1.500 | 2.89 | 4.33 | [0 - 0.5] |
returnOnAssetsTTM | 0.280 | 1.200 | 0.651 | 0.782 | [0 - 0.3] |
returnOnEquityTTM | 0.369 | 1.500 | 7.01 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.192 | -1.000 | 8.08 | -8.08 | [0 - 1] |
currentRatioTTM | 4.94 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 4.16 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.59 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.00494 | -1.500 | 9.92 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 35.54 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.894 | 2.00 | 9.70 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.893 | 2.00 | 9.55 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.00605 | -1.500 | 9.98 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.747 | 1.000 | 0.889 | 0.889 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.382 | 1.000 | 4.36 | 4.36 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 29.32 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.789 | 0.800 | 8.07 | 6.46 | [0.5 - 2] |
Total Score | 11.99 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 9.63 | 1.000 | 9.13 | 0 | [1 - 100] |
returnOnEquityTTM | 0.369 | 2.50 | 8.08 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.893 | 2.00 | 9.70 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 2.34 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.894 | 2.00 | 9.70 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.192 | 1.500 | 8.08 | -8.08 | [0 - 1] |
pegRatioTTM | 0.373 | 1.500 | -0.849 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.184 | 1.000 | 7.91 | 0 | [0.1 - 0.5] |
Total Score | 6.58 |
SciClone Pharmaceuticals,
SciClone Pharmaceuticals (Holdings) Limited, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products in the therapeutic areas of oncology and severe infection in Mainland China and internationally. The company's proprietary product is Zadaxin, which is used for the treatment of hepatitis B and hepatitis C viruses, and certain cancers, as well as for use as an immune system enhance. Its in-licensed products include Zometa for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, and hypercalcemia of malignancy; DANYELZA for the treatment of relapsed/refractory high-risk neuroblastoma; and Angiomax, an anticoagulant for use in patients undergoing percutaneous coronary intervention comprising patients with heparin-induced thrombocytopenia and thrombosis syndrome. The company's pipeline products comprise Vibativ, a bactericidal, once-daily, injectable lipoglycopeptide antibiotic for the treatment of adult patients with hospital-acquired and ventilator associated bacterial pneumonia; Omburtamab for the treatment of CNS/ leptomeningeal metastasis from neuroblastoma; RRx-001, a small molecule immunotherapeutic which treats solid tumors; PEN-866, a HSP90-binding miniature drug conjugate; HSP90-PI3K SMDC for the treatment of solid tumors; PT-112 for the treatment of late stage prostate cancer and cholangiocarcinoma; and ABTL-0812 for the treatment of endometrial/lung/pancreatic cancer. The company sells its proprietary, in-licensed, and promotion products through distributors to hospitals and pharmacies. SciClone Pharmaceuticals (Holdings) Limited was founded in 1990 and is headquartered in Shanghai, the People's Republic of China.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.